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ABSTRACT 
 
The COVID-19 pandemic triggered by SARS-CoV-2 is a worldwide health disaster. Main protease is an 
attractive drug target among coronaviruses, due to its vital role in processing the polyproteins that are 
translated from the viral RNA. There is presently no exact drug or treatment for this diseases caused by 
SARS-CoV-2. In the present study, we report the potential inhibitory activity of some FDA approved drugs 
against SARS-CoV-2 main protease by molecular docking study to investigate their binding affinity in protease 
active site. Docking studies revealed that drug Oseltamivir (anti-H1N1 drug), Rifampin (anti-TB drug), 
Maraviroc, Etravirine, Indinavir, Rilpivirine (anti-HIV drugs) and Atovaquone, Quinidine, Halofantrine, 
Amodiaquine, Tetracylcine, Azithromycin, hydroxycholoroquine (anti-malarial drugs) among others binds in the 
active site of the protease with similar or higher affinity. However, the in-silico abilities of the drug molecules 
tested in this study, further needs to be validated by carrying out in vitro and in vivo studies. Moreover, this 
study spreads the potential use of current drugs to be considered and used to comprise the fast expanding 
SARS-CoV-2 infection. 
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INTRODUCTION 
 
A new occurred human coronavirus (COVID-19) is informed in December 2019 in Wuhan, China.1,2 Afterward, 
the COVID-19 underway spreading across the world, putting the whole world on high attentive.3 The World 
Health Organization (WHO) surveillance draft in January 2020 stated that, any traveller to Wuhan, Hubei 
Province in China, two weeks earlier the onset of the signs, is supposed to be a COVID-19 case.4,5 On April 
21st, 2020, a total of 2,31,4621 confirmed infections were reported worldwide, with 1,57,847 deaths with a 
increasing mortality rate of >4.3%.5 The World Health Organization (WHO) strategy to comprise the distribution 
includes the decrease of human-to-human dispersal by preventing the interaction between individuals, 
accordingly avoiding transmission extension events and interactive critical risk evidence to all populations.5 In 
India, the first case of the COVID-19 was reported in Kerala on 30 January 2020. As of 21 April, 2020, there are 
14,255 cases and 559 deaths as reported by the Ministry of Health and Family Welfare, Government of India.6   
 
COVID-19 is a member of Betacoronaviruses similar to the Severe Acute Respiratory Syndrome Human 
coronavirus (SARS HCoV) and the also the Middle-East Respiratory Syndrome Human coronavirus (MERS 
HCoV).7 Main protease (Mpro) is the one of the greatest-characterized drug targets among coronaviruses.8 
Beside with the papain-like protease(s), this main protease enzyme is vital for processing the polyproteins that 
are translated from the viral RNA.8 This crucial function of main protease in virus duplication makes this enzyme 
a capable target for the expansion of inhibitors and possible treatment remedy for infection of novel coronavirus. 
To date, no precise therapeutic medicine or vaccine has been accepted for the management of human 
coronavirus.  
 
Some clinical trials, it has been described that anti-HIV drugs and chloroquine phosphate, an anti-malarial drug, 
has a assured therapeutic effect on the COVID-19.9 In specific, chloroquine phosphate is suggested to treat 
COVID-19 related pneumonia in larger inhabitants in the future. Subsequently, other clinical trials suggested 
that hydroxychloroquine supplementary with azithromycin is very operative in the management of the COVID-
19.10 This encouraged us to accomplish a systematic study on some clinically approved medicines using 
molecular docking and reinvestigate their biological efficacies and pharmacological properties. However, there 
is no organized study on the inhibition of the coronavirus by clinically approved drugs to the best of our 
knowledge. Hence, the present study was aimed to molecular docking studies of clinically approved drugs 
against the main protease of SARS-CoV-2. 
 
 
 
 
 
 
  
MATERIALS AND METHODS 
 
Molecular Docking Methods 
For molecular docking, Auto-Dock 4.2 software was used.11 The free energy (DG) binding of SARS-CoV-2 viral 
protease with the selected FDA approved drugs was created by means of this molecular docking package. 
Docking is a computational simulation method of a ligand binding to a receptor or enzyme and expects the 
favored orientation of binding of one molecule to the second to form a steady complex. To predict the attraction 
and activity of binding of the minor molecule to their enzyme targets by using scoring functions docking is used. 
Therefore, docking shows significant role in the rational design of medicines. The sensitivity of docking 
calculations concerning the geometry of the involvement ligand displays that even minor changes in the ligand 
structure can lead to big changes in the geometries and scores of the subsequent docked poses. 
 
Selection of Ligand 
Anti-viral and anti-malarial medications were recognized as potential coronavirus inhibitors from diverse 
literature evaluations. Total 47 FDA approved drugs were selected for molecular docking with main COVID-19 
protease. Among the 47 approved drugs, 2 drugs are anti-H1N1 drugs, 4 are anti-TB drugs, 24 are anti-HIV-1 
drugs and 17 are anti-malarial drugs are selected from PubChem database. The three-dimensional structure 
files of the selected FDA approved drugs were downloaded in SDF format from the PubChem were used for 
molecular docking. Molecular 2D structures of selected FDA approved drugs are shown in Table 1.  
 
Table 1  
Structures of clinically approved drugs 
 
Oseltamivir (anti-H1N1) 
 
Zanamivir (anti-H1N1) 
 
 
Isoniazid (anti-TB) 
 
 
 
Rifampin (anti-TB) 
 
 
Ethambutol (anti-TB) 
 
 
 
Pyrazinamide (anti-TB) 
 
 
Abacavir (anti-HIV) 
 
Atazanavir (anti-HIV) 
 
Darunavir (anti-HIV) 
 
  
Delavirdine (anti-HIV) 
 
 
Dolutegravir (anti-HIV) 
 
Doravirine (anti-HIV) 
 
 
Efavirenz (anti-HIV) 
 
 
 
 
Elvitegravir (anti-HIV) 
 
 
 
Emtricitabine (anti-HIV) 
 
 
 
Etravirine (anti-HIV) 
 
 
 
Fosamprenavir (anti-HIV) 
 
 
Indinavir (anti-HIV) 
 
 
 
Lamivudine (anti-HIV) 
 
 
 
Lopinavir (anti-HIV) 
 
 
 
Maraviroc (anti-HIV) 
 
 
 
 
 
 
  
Nevirapine (anti-HIV) 
 
 
Raltegravir (anti-HIV) 
 
 
Rilpivirine (anti-HIV) 
 
 
 
Ritonavir (anti-HIV) 
 
 
Saquinavir (anti-HIV) 
 
 
Stavudine (anti-HIV) 
 
 
 
Tenofovir (anti-HIV) 
 
 
 
Tipranavir (anti-HIV) 
 
 
Zidovudine (anti-HIV) 
 
 
Quinine (anti-malarial) 
 
 
Quinidine (anti-malarial) 
 
 
Mefloquine (anti-malarial) 
 
 
 
 
 
Chloroquine (anti-malarial) Amodiaquine (anti-malarial) Primaquine (anti-malarial) 
  
 
 
 
 
 
 
 
Halofantrine (anti-malarial) 
 
 
Sulfadoxine (anti-malarial) 
 
 
Sulfamethoxypyridazine  
(anti-malarial) 
 
 
 
Proguanil (anti-malarial) 
 
 
 
Pyrimethamine (anti-malarial) 
 
 
Tetracycline (anti-malarial) 
 
 
 
Doxycycline (anti-malarial) 
 
 
 
 
Clindamycin (anti-malarial) 
 
 
 
 
 
 
 
 
 
Azithromycin (anti-malarial) 
 
 
   
  
Artemisinin (anti-malarial) 
 
 
 
Atovaquone (anti-malarial) 
 
 
 
 
Hydroxychloroquine 
 (anti-malarial) 
 
 
 
 
Selection of Target 
The main COVID-19 protease remained used as a target to novelty repurposing candidates over computational 
selection amongst clinically accepted drugs. The study identified a list of FDA permitted 47 drugs that may form 
hydrogen bonds to key residues of amino acids within the binding pocket of viral protease and may too have a 
higher tolerance to conflict mutations. The crystal 3D structure of SARS-CoV-i2 protease (PDB ID:6LU7) 
remained obtained from Protein-Data Bank.12 (Figure-1).  
 
Figure 1 
The 3D crystal structure of SARS-CoV-2 protease (PDB ID: 6LU7) 
 
 
 
 
Meanwhile this protease has its crystal structure in a state that signifies the pharmacological target for the 
progress of new medicines to treatment diverse infectious diseases. The preparation of the target enzyme 6LU7 
with the Auto-Dock Tools software intricate addition of all H2 atoms to the enzyme, which is a step essential for 
accurate calculation of fractional atomic charges. The ligand and all water molecules were detached to make 
the structure for docking. Gasteiger charges are considered for each atom of the protein in AutoDock 4.2 
instead of Kollman charges, which were used in the earlier versions of this package. 
 
Docking Procedure 
For ligand conformational incisive, we take the ‘Lamarckian-genetic algorithm (LGA)’, which is a mixture of a 
genetic algorithm and a native search algorithm. This algorithm initially builds a population of entities, being a 
diverse casual conformation of the docked enzyme. Each distinct protein is then mutated to attain a slightly 
diverse translation and alternation and the local search algorithm then achieves energy minimizations on a user-
specified amount of the population of individuals. The entities with the low subsequent energy are moved to the 
succeeding generation and the procedure is then repetitive. This algorithm is called Lamarckian while every 
novel group of entities is allowable to receive the local search variations of their parents. 
  
 
To get many docked structures, Auto-Dock was run numerous times, and used to examine the expected 
docking energy. Rapid energy assessment was attained by pre-calculating nuclear affinity capacities for every 
atom in the compound molecule. The binding sites of the target enzyme for these molecules in the AutoGrid 
process were designated on the patterns of founded ligand-binding pockets.13 Auto-Dock Tools deliver various 
approaches to examine the outcomes of docking-simulations such as, structural resemblance, and other 
limitations like inter-molecular energy, visualizing the binding site and its energy and inhibition constant. The 
energy of interaction of every atom in the ligand was met. For each ligand, 10 best postures were made and 
scored using Auto-Dock 4.2 scoring purposes.14   
 
RESULTS 
 
Computational approaches for drug discovery and development are proven to be effective and time efficient, as 
they are not based on difficult laborious works. The protein-ligand docking elucidates the mechanism of 
inhibition along with the specificity and efficiency of that ligand as an inhibitor. The association of drug candidate 
(ligand) to its target receptor is a fundamental binding reaction and the aim of the computer-aided drug 
discovery is to find small molecules having strong inhibitory or activating action against the biological targets. 
The strength of inhibition or activation is elucidated through binding affinity.15  
 
Docking Prediction of anti-H1N1 drugs 
Oseltamivir and Zanamivir, two FDA approved drugs docked with SARS-CoV-2 main protease and obtained 
binding energy is −7.39 kcal/mol and -3.88 kcal/mol respectively (Table-2). Oseltamivir interacted with Glu:166, 
Pro:52, 168, Met:49,165, Leu:167, His:164, 41, Tyr:54, Gln:189, Arg:188, Asp:187, Thr:190 and Gln:192 at the 
binding site of this SARS-CoV-2 protease and Zanamivir interacted with Glu:166, Leu:167, Met:165, Gln:189, 
192, Thr:190, Ala:191, Pro:168, Gly:170 at the binding site of this protease (Figure 2). The results identified that 
Oseltamivir is potential inhibitor of the SARS-CoV-2 main protease. Earlier one study has reported that 
Oseltamivir is a prodrug of oseltamivir carboxylate, a potent and selective inhibitor of the neuraminidase 
glycoprotein essential for replication of influenza A and B viruses.16  
 
Table 2 
 Molecular docking analysis of anti-H1N1 drugs against COVID-19 Protease (6LU7) 
 
Sl. N 
Compound 
Name 
Binding 
energy 
(kcal/mol) 
Residue involving interaction 
No. of H 
bonds 
Interaction of 
residues forming 
H2 bonds 
1 Oseltamivir -7.39 
GLU:166, PRO:52, 168, 
MET:49,165, LEU:167, HIS:164, 
41, TYR:54, GLN:189, ARG:188, 
ASP:187, THR:190, GLN:192 
1 GLU:166 
2 Zanamivir -3.88 
GLU:166, LEU:167, MET:165, 
GLN:189, 192, THR:190, 
ALA:191, PRO:168, GLY:170 
4 
GLU:166, 
LEU:167 
 
 
Figure 2  
Docking visualisation of COVID-19 protease (6LU7) with Oseltamivir (anti-H1N1 drug) 
 
   
 
Docking Prediction of anti-TB drugs 
  
Isoniazid, Rifampin, Ethambutol and Pyrazinamide are clinically approved drugs were docked with binding 
energy -4.83, -9.41, -5.02 and -4.05 kcal/mol respectively against SARS-CoV-2 protease (Table 3). Rifampin 
showing highest binding affinity -9.41 kcal/mol among all the four drugs. The residues involved in the interaction 
with the Rifampin were Glu:166, Met:165, His:163, 172, 164, 163, Phe:140, Leu:141, 167, Ser:144, Gly:143, 
Asn;142, Pro:163, Gln:192, Cys:145, Ala:191, Thr:190 and Gln:189 (Figure 3). 
 
Table 3 
Molecular docking analysis of anti-TB drugs against COVID-19 Protease (6LU7) 
 
Sl. N Compound Name 
Binding 
energy 
(kcal/mol) 
Residue involving interaction 
No. of 
H 
bonds 
Interaction 
of residues 
forming H2 
bonds 
1 Isoniazid -4.83 
MET:49, 165, ASP:187, 
TYR:54, GLN:189, HIS:41, 
PRO:52, ARG:188 
4 
MET:49, 
TYR:54, 
ASP:187 
2 Rifampin -9.41 
GLU:166, MET:165, HIS:163, 
172, 164, 163, PHE:140, 
LEU:141, 167, SER:144, 
GLY:143, ASN;142, PRO:163, 
GLN:192, CYS:145, ALA:191, 
THR:190, GLN:189 
1 GLU:166 
3 Ethambutol -5.02 
LEU:141, ASN;142, GLU:166, 
HIS:163,172, MET:165, 
SER:144, GLY:143, CYS:145, 
PHE:140, GLY:170 
4 
LEU:141, 
ASN:142, 
GLU:166 
4 Pyrazinamide -4.05 
VAL:303, 212, THR:304, 257, 
GLN:256, GLN:306, ARG:217, 
ILE:213 
3 
VAL:303, 
THR:304, 
GLN:256 
 
 
Figure 3  
Docking visualisation of COVID-19 protease (6LU7) with anti-TB drug Rifampin 
 
 
 
Docking Prediction of anti-HIV drugs 
Twenty-four FDA approved anti-HIV drugs were docked with SARS-CoV-2 protease. Among the twenty four 
drugs, four drugs Maraviroc, Etravirine, Indinavir and Rilpivirine were showed more potential inhibitors of SARS-
CoV-2 main protease with binding affinity -10.67, -10.33, -10.00 and -9.66 kcal/mol respectively (Table 4). 
Maraviroc interacted at  His:164, 41, Tyr:54, Asp:187, Met:165, 49, Leu:167,141, Pro:168, Cys:44, 145, 
Arg:188, Gly:143, Asn:142, Ala:191, Gln:192, 189, Thr:190, Etravirine interacted at Gln:83, Lys:88, Thr:175, 
Met:82, 162, His:164, Cys:85,38, Gly:179, Pro:39, Leu:177,87, Cys:38, Tyr:37, Glu:178, Asn:84, Arg:40, 
Indinavir interacted at Glu:166, Gln:189, 192,  Cys:145, Met:49, 165, Asp:187, His:41, 164, 163, Asn:142, 
Leu:167, 141, Pro:168, Thr:190, Phe:140, Ser:144, 46, Arg:188 and Rilpivirine interacted at Glu:166, Cys:44, 
145, His:164, 41, Met:165, 49, Ala:191, Pro:168,52, Gln:189,  Tyr:54, Asp:187, Arg:188, Leu:167, Thr:190 of the 
SARS-CoV-2 main protease (Figure 4). A  joint  research  team  of  the  Shanghai  Institute  of  Materia Medica 
and Shanghai Tech University performed drug  screening  in  silicon  and  an  enzyme  activity  test,  and  they  
reported  30  anti-HIV agents  with  potential  antiviral  activity  against  SARS-CoV-2  on  January  25,  2020.17  
 
 
 
 
 
  
Table 4 
Molecular docking analysis of anti-HIV drugs against COVID-19 Protease (6LU7) 
 
Sl. N 
Compound 
Name 
Binding 
energy 
(kcal/mol) 
Residue involving interaction 
No. of 
H 
bonds 
Interaction of 
residues 
forming H2 
bonds 
1 Abacavir -7.77 
MET:49, 165, GLN:189,192, HIS:41, 
THR:190, ASP:189, TYR:54, 
PRO:52,168 LEU:50,167, ARG:188, 
GLU:166, 
1 MET:49 
2 Atazanavir -5.08 
LYS:137,5, GLU:288,290, TYR:126, 
LEU:287,286, ASP:289, VAL:125, 
PHE:3, 291, ARG:4, CYS:128, 
GLY:138, GLN:127, ALA:7, 
1 LYS:137 
3 Darunavir -6.08 
GLN:189,192, GLU:166, PHE:140, 
PRO:168, MET:165, LEU:167, 
THR:190, GLN:192, GLY:143, 
CYS:145, SER:144, HIS:163,164, 172, 
LEU:141, ASN:142, 
3 
GLN:189, 
GLU:166, 
PHE:140 
4 Delavirdine -7.89 
TYR:54, GLU:166, ALA:191, 
MET:165,49, LEU:167, 50, GLN:192, 
189, PRO:168, HIS:41,164,  ARG:188, 
ASP:187, THR:190, 
2 
TYR:54, 
GLU:166 
5 Dolutegravir -7.75 
GLU:166, MET:165, 49, GLN:192, 
THR:190, PRO:168, LEU:167, 27 
ALA:191, ARG:188, GLN:189, HIS:164, 
41, CYS:145, GLY:143, ASN:142, 
SER:144 
1 GLU:166 
6 Doravirine -8.15 
THR:190, 25,ARG:188, TYR:54, 
MET:165, 49,  ASP:187,  HIS:41, 
GLN:189, 192, GLU:166, HIS:164, 
GLY:143, LEU:27, THR:25, 
3 
THR:190, 
TYR:54, 
ARG:188 
7 Efavirenz -6.61 
GLY:143, CYS:145, ASN:142, MET:49, 
HIS:41,163, 164, THR:26, LEU:27, 141, 
SER:144, PHE:140, GLU:166, 
MET:165, GLN:189 
1 GLY:143 
8 Elvitegravir -7.98 
THR:190,ASN:142, CYS:145, 
MET:165, 49, GLN:192, 189, PRO:168, 
ARG:188, GLU:166, LEU:167, 141, 
GLY:143, SER:144, HIS:163, 164,  
PHE:140, ASP:187, 
1 THR:190 
9 Emtricitabine -4.79 
HIS:41, 164, GLU:166, MET:165,49, 
THR:190, ARG:188, GLN:192, 189, 
TYR:54, ASP:187, 
2 
HIS:41, 
GLU:166 
10 Etravirine -10.33 
GLN:83, LYS:88, THR:175, MET:82, 
162, HIS:164, CYS:85,38, GLY:179, 
PRO:39, LEU:177,87, CYS:38, TYR:37, 
GLU:178, ASN:84, ARG:40 
2 GLN:83 
11 Fosamprenavir -4.08 
ASN:203, 151, PRO:293, PHE:8,294, 
ILE:249, 200, 106, VAL:202, 104, 
GLN:110, THR:292, GLY:109, 
ASP:153, VAL:104, SER:158, 
1 ASN:203 
12 Indinavir -10.00 
GLU:166, GLN:189, 192,  CYS:145, 
MET:49, 165, ASP:187, HIS:41, 164, 
163, ASN:142, LEU:167, 141, 
PRO:168, THR:190, PHE:140, 
SER:144, 46, ARG:188 
3 
GLU:166, 
GLN:189 
13 lamivudine -4.75 
PHE:140, GLU:166, SER:144, 
CYS:145, HIS:164, 41, 163, 172, 
MET:49, 165, ASN:142,LEU:141, 
GLY:143 
5 
PHE:140, 
GLU:166, 
SER:144, 
CYS:145, 
HIS:164 
  
14 Lopinavir -6.11 
GLU:166, ASN:142, SER:144, 
HIS:163,164 PHE:140, CYS:145, 
LEU:141,167 ARG:188, MET:165, 
GLN:189,192, ALA:191, THR:190 
1 GLU:166 
15 Maraviroc -10.67 
HIS:164, 41, TYR:54, ASP:187, 
MET:165, 49, LEU:167,141, PRO:168, 
CYS:44, 145, ARG:188, GLY:143, 
ASN:142, ALA:191, GLN:192, 189, 
THR:190, 
2 
TYR:54, 
HIS:164, 
16 Nevirapine -6.44 
MET:49, 165, HIS:41, 164, SER:144, 
CYS:145, GLU:166, GLN:189, 
ASP:187, ARG:188, TYR:54 
0 0 
17 Raltegravir -7.81 
SER:144, CYS:145, GLU:166, 
PRO:168,MET:49, 165, 
HIS:41,163,172, 164, LEU:141, 167, 
PHE:140, GLY:143, ASN:142, 
GLN:189, THR:190, ARG:188, 
3 
SER:144, 
CYS:145, 
GLU:166 
18 Rilpivirine -9.66 
GLU:166, CYS:44, 145, HIS:164, 41, 
MET:165, 49, ALA:191, PRO:168,52, 
GLN:189,  TYR:54, ASP:187, 
ARG:188, LEU:167, THR:190, 
3 
HIS:164, 
CYS:44, 
GLU:166 
19 Ritonavir -8.25 
GLY:143,170, GLU:166, 
LEU:141,27,167, PHE:140, CYS:145, 
ASN:142, HIS:41, ASP:187, 
MET:49,163 ARG: 188, GLN:189,192, 
THR:190, ALA:191, GLY:170, 
PRO:168, 
1 GLY:143 
20 Saquinavir -7.55 
GLY:302, 2, ARG:298, SER:301,1, 
PRO:9, VAL:297,303, MET:6, 
CYS:300, ALA:7, PHE:8, GLY:2 
5 
ARG:298, 
GLY:302, 
SER:301 
21 Stavudine -5.38 
ARG:188, GLN:189, 192, HIS:41, 164, 
MET:165, THR:190, GLN:192, 
VAL:186, TYR:54, ASP:187, GLU:166 
2 ARG:188 
22 Tenofovir -4.40 
THR:190, GLU:166, MET:165, 49, 
ALA:191, GLN:189, 192, ARG:188, 
ASP:187, PRO:168, LEU:167, HIS:41 
2 
THR:190, 
GLU:166 
23 Tipranavir -8.30 
GLN:189, GLU:166, ASN:142, MET:49, 
CYS:145, MET:165, 49, HIS:41, 164, 
163, SER:144, 46, PHE:140, LEU:141, 
ARG:188, ASP:187, TYR:54, GLY:143, 
3 
GLN:189, 
ASNl142, 
GLU:166 
24 Zidovudine -6.31 
ASP:187, GLU:166, ARG:188, TYR:54, 
MET:165,49, GLN:189, HIS:164,41, 
PHE:181, PRO:52CYS:44 
2 
ASP:187, 
GLU:166 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4  
Docking visualisation of COVID-19 protease (6LU7) with anti-HIV drugs, Maraviroc (A), Etravirine (B), 
Indinavir (C) and Rilpivirine (D). 
 
(A) Maraviroc 
   
 
(B) Etravirine 
   
 
(C) Indinavir 
   
 
(D) Rilpivirine 
   
  
Docking Prediction of anti-malarial drugs 
Seventeen clinically approved anti-malarial drugs were docked with SARS-CoV-2 protease. Out of seventeen, 
seven drugs were showed more potential inhibitors of SARS-CoV-2 main protease. Atovaquone, Quinidine, 
Halofantrine, Amodiaquine, Tetracycline, Azithromycin and hydroxychloroquine docked with binding affinity -
8.95, -8.84, -8.68, -8.65, -8.4, -8.32 and -8.30 kcal/mol against SARS-CoV-2 main protease (Table 4). Docking 
visualization of 6LU7 with seven anti-malarial drugs was showed in Figure 5.  Among the seven potent inhibitors 
Atovaquone was more potent with binding affinity -8.95 kcal/mol. Asn:142, Glu:166, Leu:141, Met:49, 165, 
Cys:44, Pro:52, Tyr:54, Arg:188, Asp:187, His:41,164, 163, 172, Phe:140 and Gln:189 are the amino acid 
residues involved in the interaction with Atovaquone (Figure 5). As these residues play an important role during 
protein-ligand interaction, they may serve as a biomarker during the drug discovery process.18 
 
Table 5 
Molecular docking analysis of anti-malarial drugs against COVID-19 Protease (6LU7) 
 
Sl. N Compound Name 
Binding 
energy 
(kcal/mol) 
Residue involving interaction 
No. of 
H 
bonds 
Interaction of 
residues 
forming H2 
bonds 
1 Quinine -7.86 
GLN:189, HIS:172,41, 164, 163 
CYS:145, MET:165, 49, GLU:166, 
ARG:188, TYR:54, ASN:142, 
PHE:140, SER:144, LEU:141, 
GLY:143, ASP:187 
1 GLN:189 
2 Quinidine -8.84 
GLN:189, MET:165, 49, TYR:54, 
PRO:52, HIS:41, 164, PHE:181, 
ASP:187, GLU:166, ASN:142, 
CYS:145, SER:144, GLY:143, 
THR:26, 25, LEU:27, VAL:186 
1 GLN:189 
3 Mefloquine -7.47 
GLN:189,192, TYR:54, GLU:166, 
ARG:188, ASP:187, MET:49, 
LEU:167, 141, THR:190, MET:165, 
HIS:163, 172, 164,41, LEU:167, 
CYS:145, PHE:140, SER:144, 
3 
GLN:189,192, 
TYR:54 
4 Chloroquine -7.62 
HIS:164,163, 41, 172, ARG:188, 
PRO:52, TYR:54, MET:49, 165, 
ASP:187, GLN:189, GLU:166, 
LEU:141, SER:144, CYS:145, 
ASN:142, PHE:140 
1 HIS:164 
5 Amodiaquine -8.65 
LEU:141,SER:144, HIS:41, 172, 
163, 164, GLN:189, 192, 
MET:165,49,PHE:140,  ASP:187, 
ARG:188, THR:190, GLN:192, 
GLU:166, ASN:142, GLY:143, 
CYS:145, 
2 
LEU:141, 
SER:144 
6 Primaquine -7.15 
GLU:166, LEU:167, GLY:170, 
ASP:187, GLN:189, MET:165, 
ARG:188, GLN:192, THR:190, 
PRO:168 
4 
GLU:166, 
LEU:167 
7 Halofantrine -8.68 
GLN:192, 189, THR:190, ARG:188, 
GLU:166, CYS:145, MET:49, 165, 
HIS:164, ASP:187, TYR:54, 
PRO:168, LEU:167, 141,SER:144, 
HIS:163, GLY:143,  
2 
THR:190, 
GLN:192 
8 Sulfadoxine -6.47 
HIS:164,41, 172, 163, SER:144, 
LEU:141, CYS:145, MET:49, 165 
GLU:166, PRO:52, TYR:54, 
ARG:188, ASP:187, GLN:189, 
ASN:142 
3 
SER:144, 
LEU:141, 
HIS:164 
9 
Sulfamethoxypyrid
azine 
-7.40 
HIS:163,164, 41,172, 
SER:144,LEU:141,MET:49, 165, 
ASP:187,ASN:142, PHE:140, 
GLU:166, GLN:189, TYR:54, 
PRO:52, CYS:145, ASN:142, 
GLY:143, 
4 
HIS:163,164, 
SER:144, 
LEU:141 
  
10 Proguanil -7.81 
HIS:163, 172 GLU:166, LEU:141, 
PHE:140, MET:165, SER:144, 
GLY:143, ASN:142, CYS:145 
4 HIS:163 
11 Pyrimethamine -6.85 
ASN:142, GLU:166, PHE:140, 
HIS:172, 163, 41, LEU:141, 
SER:144, MET:165, CYS:145, 
MET:49, GLY:143, 
3 
ASN:142, 
GLU:166, 
PHE:140 
12 Tetracycline -8.40 
GLU:166, ASN:142, LEU:141, 
SER:144, CYS:145, MET:165,49, 
GLN:189, ASP:187, ARG:188, 
PHE:140, HIS:41,163,172, GLY:143 
6 
GLU:166, 
LEU:141, 
SER:144, 
CYS:145, 
ASN:142, 
13 Doxycycline -8.30 
GLN:189, ASN:142, GLU:166, 
SER:144, MET:165, HIS:172, 163, 
PHE:140, LEU:141, CYS:145 
6 
GLN:189, 
ASN:142, 
GLU:166, 
SER:144 
14 Azithromycin -8.32 
ILE:152, PHE:294, 8, ARG:198, 
PRO:9, VAL:297, SER:301, 
ASP:153, TYR:154, ASN:151 
1 ILE:152 
15 Artemisinin -7.63 
MET:165, 49, HIS:41, 164, 
ARG:188, GLU:166, GLN:189, 
CYS:145, 44, TYR:54, ASP:187, 
0 0 
16 Atovaquone -8.95 
ASN:142, GLU:166, LEU:141, 
MET:49, 165, CYS:44, PRO:52, 
TYR:54, ARG:188, ASP:187, 
HIS:41,164, 163, 172, PHE:140, 
GLN:189 
1 ASN:142 
17 
Hydroxychloroquin
e 
-8.30 
GLN:189, ARG:188, MET:165, 
TYR:54, ASP:187, 
HIS:41,172,163,164, PHE:140, 
LEU:141, CYS:145, SER:144, 
ASN:142, GLY:143, GLU:166 
1 GLN:189 
 
 
Figure 5.  
Docking visualisation of COVID-19 protease (6LU7) with anti-malarial drugs, Atovaquone (A), Quinidine (B), 
Halofantrine (C), Amodiaquine (D), Tetracycline (E), Azithromycin (F) and hydroxychloroquine (G) 
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This study focused on identification of potential inhibitors against SARS-CoV-2 from corona virus to control the 
viral replication. Outcomes from the In silico molecular docking study maintained the great inhibitory efficacy of 
the one anti-H1N1 drug (Oseltamivir), one anti-TB drug (Rifampin), four anti-HIV drugs (Maraviroc, Etravirine, 
Indinavir, Rilpivirine) and seven anti-malarial drugs (Atovaquone, Quinidine, Halofantrine, Amodiaquine, 
Tetracylcine, Azithromycin, hydroxycholoroquine) since they could launch H2 bonds with different amino acid 
residues that caused in an inhibition of SARS-CoV-2 protease activity with higher binding affinity ranging from (-
10.67 to -8.3 kcal/mol). Thus, the projected binding interactions of the dynamic molecules with the protease by 
the docking study evidently established their inhibitory strength towards catalytic response of the protease. This 
study provides the support of the repurposed drugs, which may be helpful for the treatment of novel coronavirus 
disease and can serve as potential drug candidates to curb the ongoing and ever enlarging COVID-19 pandemic. 
Since all the drugs used in this study are of known pharmacokinetics standards and approved by FDA for human 
use they do not need to undergo specific long term clinical trials and therefore can fasten up the process of the 
therapeutics development. 
 
DISCUSSION 
 
Coronavirus fits to a set of viruses which can contaminate vertebrate animals and human. It has slaughtered 
thousands of individuals around the world with growth in mortality rate each single day. Digestive, central nervous 
system, liver, respiratory systems of humans and animlas hampered by this virus infection.19 Our study was 
focused on the FDA approved drugs against the main protease in coronavirus, as a possible beneficial target for 
the management of coronavirus. 6LU7 (PDB ID) is the major protease in COVID-19 that has been relocated and 
structured in PDB newly and is available to everybody in the world (Figure 1). For the proteolytic maturation of 
virus, the protease is precise significant. Protease has been studied as a possible target to avoid the extent of 
contamination by inhibiting viral polyprotein cleavage via blocking active sites of the protein. With this new finding 
of protease assembly in COVID-19, has providing an enormous chance to recognize possible drug candidates for 
the management of coronavirus.20 In this study, we have applied a computational approach of FDA approved 
drugs in order to find a specific therapeutic possible agent against COVID-19. We have selected 47 FDA 
approved antiviral, anti-H1N1, anti-TB and anti-viral drugs and retrived directly from the PubChem (National 
Library of Medicine). Molecular docking was accomplished with the 47 drugs against COVID-19 structure. 
 
Molecular docking is a computational technique which aims to find non-Covalent binding among protein (receptor) 
and a ligand/inhibitor (small molecule). For recognized binding site, the docking expects the method of interaction 
among a target protein and a ligand. Binding energy proposes the attraction of an exact ligand and asset by 
which a ligand interacts with and binds to the pocket of a target protein. A drug with a lesser binding energy (ΔG) 
  
is chosen as a probable drug candidate. In order to recognize the effect of active antiviral drugs on COVID-19, 47 
FDA approved antiviral compounds were selected and performed molecular docking against COVID-19. Docking 
results of SARS-CoV-2 protease with selected 47 drugs out of the selected 13 showed best docking score and 
were found to be best molecules at the target site of the protein. Out of the 13 drugs, Maraviroc exhibited the best 
docked score (-10.67 kcal/mol) with SARS-CoV-2 protease. HIS:164, 41, TYR:54, ASP:187, MET:165, 49, 
LEU:167,141, PRO:168, CYS:44, 145, ARG:188, GLY:143, ASN:142, ALA:191, GLN:192, 189 and THR:190 are 
the amino acid residues participating in the interaction at the binding pocket of SARS-CoV-2 protease (Figure 
4A). 
 
Maraviroc is an effective anti-retroviral agent permitted for the treatment of HIV-1 infection that blocks interaction 
among the virus and the CCR5 co-receptor, a critical step in the HIV-1 replication.  Earlier clinical trials of this 
drug have established the efficacy, tolerability, and safety of maraviroc in both treatment-naive and treatment-
experienced patients.21,22 Among the 17 anti-malarial approved drugs, Atovaquone presented best docking score 
(-8.95 kcal/mol) and ASN:142, GLU:166, LEU:141, MET:49, 165, CYS:44, PRO:52, TYR:54, ARG:188, ASP:187, 
HIS:41,164, 163, 172, PHE:140, GLN:189 are the amino acid residues participating in the interaction at the 
binding pocket of SARS-CoV-2 protease (Figure 5A). Recent studies also explores that, Atovaquone significantly 
inhibited ZIKV (Zika virus) in human placental JEG3 cells in vitro.23 
 
CONCLUSION 
 
The present study concludes that, thirteen clinically approved drugs are identified as potent inhibitors against 
SARS-CoV-2 protease activity. These outcome afford a strong foundation for the use of these drugs are for 
CORONA management. Moreover, the dynamic ligands inhibited the catalytic response of protease by blocking 
the residues of amino acids intricate in the processing and strand transmission reactions. The interactions by the 
structural model at the protease active site can afford a valuable guide for additional strategies for structure-
based medicines and development of new operative inhibitors of SARS-CoV-2 protease. Therefore, the effect of 
these inhibitors can be further revealed through in vitro and in vivo analysis in the termination of intracellular 
replication of corona virus, prior to the use as drugs in humans. 
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